Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARB001
- Development stage
- Preclinical
- Lead developer
- Arbele
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
ARB001 is a preclinical-stage drug candidate developed by Arbele Corp. It is designed as a Cadherin-17 (CDH17) antagonist, targeting Cadherin-17 (CDH17), which is implicated in the progression of various gastrointestinal and digestive system cancers. The modality for ARB001 has been described as both a CAR-NK cell therapy and a bispecific antibody in different sources, but its primary mechanism of action involves antagonism of CDH17 to inhibit tumor growth. Its main therapeutic focus is on neoplasms, particularly metastatic colorectal carcinoma and other gastrointestinal tumors[1][5]. As of the latest updates, development remains at the preclinical stage[1][5].
- Other names
- CDH17-CAR-T cell therapyCDH-17-CAR-T cell therapyCDH 17-CAR-T cell therapy
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on ARB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARB001.